Mysterious Side of COVID-19 Pandemic: Children

Özdemir, Öner; Melek Arsoy, Hacer Efnan

doi:10.4274/imj.galenos.2020.13463

Mysterious Side of COVID-19 Pandemic: Children

Hacer Efnan MELEK ARSOY, (Sakarya Üniversitesi Eğitim ve Araştırma Hastanesi, Çocuk Sağlığı ve Hastalıkları Kliniği, Sakarya, Türkiye)

Öner ÖZDEMİR (Sakarya Üniversitesi, Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Alerji ve İmmünoloji Bilim Dalı, Sakarya, Türkiye)

İstanbul Medical Journal

1 0

Yıl: 2020 Cilt: 21 Sayı: 4 Sayfa Aralığı: 242 - 257 Metin Dili: İngilizce DOI: 10.4274/imj.galenos.2020.13463 İndeks Tarihi: 25-10-2020

Mysterious Side of COVID-19 Pandemic: Children

Öz:

As of December 31, 2019, the Severe Acute Respiratory syndromeCoronavirus-2 (SARS-CoV-2) was identified as the cause ofa cluster of pneumonia cases in Wuhan, a city in the Hubeiprovince of China and has been responsible for over 40,000deaths worldwide. Data on the epidemiologic characteristicsand clinical features, diagnosis and management of infectedchildren are limited. Despite the high mortality rate of MiddleEast Respiratory syndrome and SARS in adults, the morbidityand mortality rates in children are low. Understanding therole of paediatric population in the transmission dynamicsof the outbreak is important and critical for effective diseasecontainment with respect to the public health. The aetiologyof the milder disease form caused by the CoVs, including SARSCoV-2, remains unknown in children. İnfected children may beasymptomatic or have fever, dry cough, and fatigue and rarelyhave severe disease. Asymptomatic children may be driving thetransmission of CoV more than we realise. Early diagnoses andtreatment along with careful isolation can limit the outbreak.Children may help in future development of immunotherapyand vaccines for SARS-CoV-2. This review aimed to summarisecurrent data available on SARS-CoV-2 pandemic to manage thediagnosis, treatment, and prevention of CoV disease 2019 inthe paediatric population.

Anahtar Kelime:

COVID-19 Pandemisinin Gizemli Yanı: Çocuklar

Öz:

31 Aralık 2019’dan itibaren dünya çapında 40,000’den fazla ölümden sorumlu olan 2019’un yeni koronavirüsü [Şiddetli Akut Solunum sendromu - Koronavirüs-2 (SARS-CoV-2)], Çin’in Hubei eyaletindeki bir şehir olan Wuhan’da pnömoni olgularının nedeni olarak tanımlanmıştır. Enfekte çocukların epidemiyolojik özellikleri ve klinik özellikleri tanı, tedavisi ile ilgili veriler sınırlıdır. Orta Doğu Solunum sendromu ve SARS’da yetişkinlerde yüksek mortalite oranına rağmen, çocuklarda ölüm ve morbidite oranları azdır. Salgının bulaşma dinamiklerinde pediyatrik popülasyonun rolünün anlaşılması, halk sağlığı kontrolünün etkili olması için önemli ve kritiktir. Çocukların SARS-CoV-2 de dahil olmak üzere koronavirüslerin neden olduğu hastalıkları neden daha hafif atlattıkları bilinmemektedir. Enfekte çocukta semptom olmayabileceği gibi ateş, kuru öksürük ve yorgunluk olabilir ya da nadiren kritik seyredebilir. Asemptomatik çocuklar virüsün farkettiğimizden daha fazla yayılmasına neden olabilir. Erken teşhis ve tedavi ve dikkatli izolasyon salgını sınırlandırabilir. Çocuklar SARS-CoV-2 için immünoterapi ve aşıların gelecekteki gelişimine yardımcı olabilir. Bu derlemede pediyatrik popülasyonda COVID-19’un tanısı, tedavisi ve önlenmesine rehberlik etmek için SARS-CoV-2 pandemisi hakkındaki mevcut veriler özetlenmiştir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. World Health Organization. Novel coronavirus, China. 2020 https://www.who. int/csr/don/12-january-2020-novel-coronavirus-china/en/ (Accessed on March 19, 2020).
2. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. WHO Technical Guidance 2020. https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/technical-guidance/namingthe-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it (Accessed on March 15, 2020).
3. Ashour HM, Elkhatib WF, Rahman MM, Elsabrawy HA. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens 2020; 9: 186.
4. Favre G, Pomar L, Musso D, Baud D. 2019-nCoV epidemic: what about pregnancies? Lancet 2020; 395: 40.
5. Memish Z, Perlman S, Kerkhove MDV, Zumla A. Middle East respiratory syndrome. Lancet 2020; 395: 1063-77.
6. Zhang YH, Lin DJ, Xiao MF, Wang JC, Wei Y, Lei ZX, et al. 2019-novel coronavirus infection in a three-month-old baby. Zhonghua Er Ke Za Zhi 2020; 58: E006.
7. Cai JH, Wang XS, Ge YL, Xia AM, Chang HL, Tian H, et al. First case of 2019 novel coronavirus infection in children in Shanghai. Zhonghua Er Ke Za Zhi 2020; 58: E002.
8. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. Jama 2020;323:1335.
9. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) United States, February 12-March 16, 2020. Weekly 2020; 69; 343-6.
10. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA 2020; 323: 1239-42.
11. Korea Centers for Disease Control and Coordination. Updates on COVID-19 in Korea. 2020 March 14. https://www.cdc.go.kr/board/board. es?mid=a30402000000&bid=0030 (Accessed on March 18, 2020).
12. Woo PC, Huang Y, Lau SK, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses 2010; 2: 1804-20.
13. Geller C, Varbanov M, Duval R. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses 2012; 4: 3044-68.
14. Perlman S. Another decade, another coronavirus. N Engl J Med 2020; 382: 760-2.
15. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-33.
16. Jubeit B, Narayan O, Johnson RT. Patognezis of human poliovirus infection in mice. Clinical and pathological studies. J Neuropathol Exp Neurol 1980; 39: 138-48.
17. Lee P. Are children less susceptible to COVID-19? Journal of Microbiol Immunol Infect 2020; 53: 371-2.
18. Gu H, Xie Z, Li T, Zhang S, Lai C, Zhu P, et al. Anjiotensin-converting enzyme 2 inhibits lung injury by respiratory syncytial virus. Scientific Reports 2016; 6: 19840.
19. Zhao Y, Zhao Z, Wang Y, Zhao Y, Ma Y. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv. 2020. doi: https:// doi.org/10.1101/2020.01.26.919985. [Epub ahead of print].
20. Liu J, Liu Y, Xiang P, Pu L, Xiong X, Li C, et al. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 Novel Coronavirus in the early stage. Med Rxiv 2020.
21. Cao Q, Chen YC, Chen LC, Chiu CH. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. Journal of the Formosan Medical Association 2020; 119: 670-3.
22. Doremalen VN, Bushmaker T, Morris DH, Holbrook MG, Williamson BN, Tamin A, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382: 1564-7.
23. Anıl M, Besli E, Duman M, Erkek N, Derinöz O, Tekin D et al. Çocuk acil servisi CoVID-19 olgu yönetim algoritmaları. Çocuk acil tıp ve yoğun bakım derneği yayınları 2020; 1: 1.
24. Chen C, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020; 395: 809-15.
25. Zhu H, Wang L, Fang C. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr 2020; 9: 51-60.
26. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, Possible vertical transmission of sars-cov-2 from an infected mother to her newborn. research letter. JAMA 2020; 323: 1846-8.
27. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382: 929‐36.
28. Chan JF, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novelcoronavirus indicating person-toperson transmission: a study of a family cluster. Lancet 2020; 395: 514-23.
29. Chen C, Gao G, Xu Y, Pu L, Wang Q, Wang L, et al. SARS-CoV-2-Positive sputum and feces after conversion of pharyngeal samples in patients with COVID-19. Ann Intern Med 2020: 20-0091.
30. Wang L, Li X, Chen H, Yan S, Li Y, Li D, et al. SARS-CoV-2 infection does not significantly cause acute renal injury: an analysis of 116 hospitalized patients with COVID-19 in a single hospital, Wuhan, China. Med Rxiv 2020.
31. Liu Y, Yan L, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. The Lancet Infect Dis 2020; 20: 656-7.
32. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith H, et al. The incubation period of 2019‐nCoV from publicly reported confirmed cases: estimation and application. Med Rxiv 2020: 20-0504.
33. Lu X, Zhang L, Du H, Shao J, Peng X, Liu Z, et al. SARS-CoV-2 infection in children. N Engl J Med 2020; 382: 1663-5.
34. Liu W, Zhang Q, Chen J, Xiang R, Song H, Liang L, et al. Detection of covid-19 in children in early january 2020 in Wuhan, China. N Engl J Med 2020; 382: 1370-1.
35. Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020 February. doi:10.1093/cid/ciaa198.
36. Ji L, Chao S, Wang Y, Li XJ, Mu XD, Lin MG, et al. Clinical features of pediatric patients with COVID19: a report of two family cluster cases. World J Pediatr 2020: 1-4.
37. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in china. Pediatrics 2020.
38. Yang P, Liu P, Li D,Zhao D. Corona virus disease 2019, a growing threat to children? J Infect 2020; 80: 671-93.
39. Cui Y, Tian M, Huang D, Wang X, Yuying H, Fan L, et al. A 55-day-old female infant infected with covid 19: presenting with pneumonia, liver injury, and heart damage. J Infect Dis 2020; 221: 1775-81.
40. Available from URL: https://irannewsdaily.com/2020/03/iran-35-day-oldbaby-tests-positive-for-covid-19/website. with-covid-19/6058789/ (Accessed on March 19, 2020).
41. Available from URL: https://abc11.com/health/illinois-reports-death-ofinfant-with-covid-19/6058789/ (Accessed on March 19, 2020).
42. https://www.channelnewsasia.com/news/world/coronavirus-covid-19-ukboy-dies-12596462?utm_source=headtopics&utm_medium=news&utm_ campaign=2020-04-01(Accessed on March 19, 2020).
43. Zeng LK, Tao XW, Yuan WH, Wang J, Liu X, Liu ZS. First case of neonate infected with novel coronavirus pneumonia in China. Chin J Pediatr 2020; 58: 009.
44. Deng H, Zhang Y, Wang Y, Li F. Two cases of 2019 novel coronavirus infection in children. Chin Pediatr Emerg Med 2020; 27: E001-E001.
45. Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr 2020.
46. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med 2020.
47. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. Lancet Respir Med 2020; 8: 475- 81.
48. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-13.
49. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol 2020; 55: 1169-74.
50. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497- 506.
51. Gao ZC. Efficient management of novel coronavirus pneumonia by efficient prevention and control in scientific manner. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: 163-6.
52. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 Cases. Radiology. 2020. doi: 10.1148/radiol.2020200642. [Epub ahead of print].
53. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 20: 425-34.
54. Zhou C, Gao C, Xie Y. COVID-19 with spontaneous pneumomediastinum. Lancet 2020; 20: 510.
55. Pan F, Ye T, Sun P, Gui S, Liang B, Lingli L, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology 2020; 295: 200370.
56. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid igm-igg combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020.
57. TC Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü COVID -19 (SARS-CoV2 Enfeksiyonu) Rehberi. Bilim kurulu çalışması. 2020 Mar 23. (Accessed on March 25, 2020).
58. Sağlık Bakanlığı Ulusal CoVID-2 acile kabul algoritması, T.C. Sağlık Bakanlığı, 2020 Mar. (Accessed on March 25, 2020).
59. Sağlık Bakanlığı Ulusal CoVID-2 tanı tedavi takip algoritması, T.C. Sağlık Bakanlığı, 2020 Mar. (Accessed on March 25, 2020).
60. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance 2020 Mar 13. Avaliable fom URL: https://www.who.int/publications-detail/clinicalmanagement-of-severe-acute-respiratory-infection-when-novel-coronavirus- (ncov)-infection-is-suspected. (Accessed on March 15, 2020).
61. Available from URL: https://dgsurgent.sante.gouv.fr/dgsurgent/inter/ detailsMessageBuilder.do?id=30500&cmd=visualiser Message (Accessed on March 19, 2020).
62. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020; 368: m1086.
63. World Health Organization. Now Doesn’t Recommend Avoiding Ibuprofen For COVID-19 Symptoms. Science Alert 2020. Available from URL: https://www. sciencealert.com/who-recommends-to-avoid-taking-ibuprofen-for-covid-19- symptoms. March 2020. (Accessed on March 25, 2020).
64. European Medicines Agency. EMA gives advice on the use of non-steroidal antiinflammatories for COVID-19. Available from URL: https://www.ema.europa. eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatoriescovid-19. 2020 Mar. (Accessed on March 25, 2020).
65. Wang XF, Yuan J, Zheng YJ, Chen J, Bao YM, Wang YR, et al. Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen. Zhonghua Er Ke Za Zhi 2020; 58: E008.
66. Wang BX, Fish EN. Global virus outbreaks: interferons as 1st responders. Semin Immunol 2019; 43: 101300.
67. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014; 20: 42-6.
68. Shen KL, Shang YX, Zhang GC, Xu BP, Fu Z, Cao L, et al. Expert consensus on rational application of interferon α in pediatrics. Chin J Appl Clin Pediatr 2018; 33: 1301-8.
69. Xu YL, Li Y, Chen YP, Xin SX, Xie L, Liang YD, et al. A multicenter controlled clinical study on the efcacy and safety of recombinant human interferon α2b spray in the treatment of hand, foot and mouth disease in children. Chin J Infect 2018; 36: 101-6.
70. Shen KL, Shang YX, Zhang H. A multicenter, randomized, controlled clinical study on the efcacy and safety of recombinant human interferon 2b spray (pseudomonas) in the treatment of acute upper respiratory tract infection in children. Chin J Appl Clin Pediatr 2019; 34: 1010-6.
71. Gao H, Zhang LL, Wei Q, Duan ZJ, Tu XM, Yu ZA, et al. Preventive and therapeutic effects of recombinant IFN-α2b nasal spray on SARS-CoV infection in Macaca mulata. Chin J Exp Clin Virol 2005; 19: 207-11.
72. Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E. Ribavirin and interferon‐α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases. Antivir Ther 2015; 20: 87‐91.
73. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, et al. Diagnosis and treatment recommendations forpediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr 2020: 1-7.
74. Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon‐alpha for Middle East respiratory syndrome. Antivir Ther 2016; 21: 455‐9.
75. Çin Sağlık Halk Cumhuriyeti Ulusal Sağlık Kurulu. Yeni koronavirüs enfeksiyonu pnömoni tanı ve tedavi planı (deneme versiyonu 5) (2020/02/04 ) [ 2020/02/05.] http: //www.nhc.gov.cn / xcs / zhengcwj / 202001 /4294563ed35b43209b31739bd0785e67 / files / 7a9309111267475a99d4306962c8bf78.pdf (Accessed on March 20, 2020).
76. Luca DD. Managing neonates with respiratory failure due to SARS-CoV-2. Lancet 2020; 4: 8.
77. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11: 222-3.
78. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-71.
79. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020; 1-13.
80. Gilead Sciences. Study to evaluate the safety and antiviral activity of Remdesivir (GS-5734) in participants with severe coronavirus disease (CoVID-2) Clinical Trials 2020 March. ClinicalTrials.gov. (Accessed on March 25, 2020).
81. Jackson Health System / University of Miami Health System .COVID-19 Confirmed or highly suspected-investigational treatment protocol, March 20,2020. https://jacksonhealth.org/coronavirus-disease-2019-covid-19/#gref (Accessed on March 25, 2020).
82. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. Arbidol: a broad‐spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008; 15: 997‐1005.
83. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020; 14: 69-71.
84. Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med 2006; 3: 343.
85. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014; 14: 1090-5.
86. Shalhoub S, Farahat F, Al-Jiffri A, Simhairi R, Shamma O, Siddiqi N, et al. IFNα2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015; 70: 2129-32.
87. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J. Ribavirin and interferon‐beta synergistically inhibit SARS‐associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 2005; 26: 905‐8.
88. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-71.
89. Chen X, Xu Z, Zeng S, Wang S, Wang X, Liu W, et al. The molecular aspect of antitumor effects of protease inhibitor nafamostat mesylate and its role in potential clinical applications. Front Oncol 2019; 9: 852.
90. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020: 105949.
91. Michigan Medicine University of Michigan. Inpatient Guidance For Treatment of CoVID-19 in Adults and Children. http://www.med.umich.edu/asp/pdf/ adult_guidelines/COVID-19-treatment.pdf. (Accessed on March 25, 2020).
92. Mehta P, McAuley FD, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033-4.
93. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 2016; 44: 275-81.
94. World Health Organization. Coronavirus disease (COVID-19) technical guidance: Patient management. Available from URL: https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/technical-guidance/patientmanagement (Accessed on February 02, 2020)
95. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395: 473.
96. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020; 395: 683-4.
97. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIG: Rare incidents blemish an excellent safety record. Neurology 2003; 60: 1736‐7.
98. Mair‐Jenkins J, Saavedra‐Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta‐analysis. J Infect Dis 2015; 211: 80‐90.
99. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2: 69.
100. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-71.
101. Chen L, Liu P, Gao H, Sun B, Chao D, Wang F, et al. Inhalation of nitric oxide in the treatment of severely acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis 2004; 39:1531-5.
102. Mallinckrodt Pharmaceuticals. Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory Agencies. From the Prnewswire website. https://www.prnewswire.com/news-releases/ mallinckrodt-evaluates-the-potential-role-for-inhaled-nitric-oxide-to-treatcovid-19-associated-lung-complications-engages-with-scientific-governmental-and-regulatory-agencies-301022189.html (Accessed on March 24, 2020).
103. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network‐based drug repurposing for human coronavirus. Med Rxiv. Accessed on 2020 March 25. https://doi.org/10.1101/2020.02.03.20020263. [Epub ahead of print].
104. Pharmacists advancing healthcare. Assessment of Evidence for COVID-19- Related Treatments. ASHP (Pharmacists advancing healthcare) guidance. 27 March 2020. https://www.ashp.org/Pharmacy-Practice/Resource-Centers/ Coronavirus (Accessed on March 29, 2020).
105. Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med. 2020 March 13. doi: 10.1016/S2213-2600(20)30119-3. (Accessed on March 25, 2020).
106. Committee on Obstetric Practice.. ACOG committee opinion. Antenatal corticosteroid therapy for fetal maturation. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 78: 95-7.
107. Wang J, Qi H, Bao L, Li F, Shi Y. A contingency plan for the management of the 2019 novel coronavirus outbreak in neonatal intensive care units. Lancet Child Adolesc Health 2020; 4: 258-9.
108. Mulangu S, Dodd LE, Davey RT Jr, Mbaya OT, Proschan M, Mukadi D et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293-303.
109. Baud D, Giannoni E, Pomar L, Qi X, Nielsen-Saines K, Musso D, et al. COVID-19 in pregnant women - Authors’ reply. Lancet Infect Dis. 2020 March 17, doi: 10.1016/S1473-3099(20)30192-4. (Accessed on March 25, 2020).
110. Coronavirus (COVID-19) Infection in Pregnancy Information for healthcare professionals Version 5. 28 March, 2020 Royal College of Obstetricians and gynaecologist. Available from URL: https://www.rcog.org.uk/globalassets/ documents/guidelines/2020-03-28-covid19-pregnancy-guidance.pdf (Accessed on March 29, 2020).
111. Wang G, Zhang Y, Zhao J, Zhang J, Jiang F. Mitigate the effects of home confinement on children during the COVID-19 outbreak. Lancet 2020; 395: 945-7.
112. Sprang G, Silman M. Posttraumatic stress disorder in parents and youth after health-related disasters. Disaster Med Public Health Prep 2013; 7: 105-10.
113. Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health. 2020 March 19. doi: 10.1016/S2214-109X(20)30114-5. [Epub ahead of print]. (Accessed on March 26, 2020).
114. Xu X. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry (COVID-19). http://www.chictr.org.cn/ showprojen.aspx?proj=49409 (Accessed on March 15, 2020).

APA	Melek Arsoy H, Özdemir Ö (2020). Mysterious Side of COVID-19 Pandemic: Children. , 242 - 257. 10.4274/imj.galenos.2020.13463
Chicago	Melek Arsoy Hacer Efnan,Özdemir Öner Mysterious Side of COVID-19 Pandemic: Children. (2020): 242 - 257. 10.4274/imj.galenos.2020.13463
MLA	Melek Arsoy Hacer Efnan,Özdemir Öner Mysterious Side of COVID-19 Pandemic: Children. , 2020, ss.242 - 257. 10.4274/imj.galenos.2020.13463
AMA	Melek Arsoy H,Özdemir Ö Mysterious Side of COVID-19 Pandemic: Children. . 2020; 242 - 257. 10.4274/imj.galenos.2020.13463
Vancouver	Melek Arsoy H,Özdemir Ö Mysterious Side of COVID-19 Pandemic: Children. . 2020; 242 - 257. 10.4274/imj.galenos.2020.13463
IEEE	Melek Arsoy H,Özdemir Ö "Mysterious Side of COVID-19 Pandemic: Children." , ss.242 - 257, 2020. 10.4274/imj.galenos.2020.13463
ISNAD	Melek Arsoy, Hacer Efnan - Özdemir, Öner. "Mysterious Side of COVID-19 Pandemic: Children". (2020), 242-257. https://doi.org/10.4274/imj.galenos.2020.13463

APA	Melek Arsoy H, Özdemir Ö (2020). Mysterious Side of COVID-19 Pandemic: Children. İstanbul Medical Journal, 21(4), 242 - 257. 10.4274/imj.galenos.2020.13463
Chicago	Melek Arsoy Hacer Efnan,Özdemir Öner Mysterious Side of COVID-19 Pandemic: Children. İstanbul Medical Journal 21, no.4 (2020): 242 - 257. 10.4274/imj.galenos.2020.13463
MLA	Melek Arsoy Hacer Efnan,Özdemir Öner Mysterious Side of COVID-19 Pandemic: Children. İstanbul Medical Journal, vol.21, no.4, 2020, ss.242 - 257. 10.4274/imj.galenos.2020.13463
AMA	Melek Arsoy H,Özdemir Ö Mysterious Side of COVID-19 Pandemic: Children. İstanbul Medical Journal. 2020; 21(4): 242 - 257. 10.4274/imj.galenos.2020.13463
Vancouver	Melek Arsoy H,Özdemir Ö Mysterious Side of COVID-19 Pandemic: Children. İstanbul Medical Journal. 2020; 21(4): 242 - 257. 10.4274/imj.galenos.2020.13463
IEEE	Melek Arsoy H,Özdemir Ö "Mysterious Side of COVID-19 Pandemic: Children." İstanbul Medical Journal, 21, ss.242 - 257, 2020. 10.4274/imj.galenos.2020.13463
ISNAD	Melek Arsoy, Hacer Efnan - Özdemir, Öner. "Mysterious Side of COVID-19 Pandemic: Children". İstanbul Medical Journal 21/4 (2020), 242-257. https://doi.org/10.4274/imj.galenos.2020.13463